MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA

Journal of Cellular Physiology

Volumn 230, Issue 3, 2015, Pages 535-545

  Qu, Juan ^a   Zhao, Liang ^b   Zhang, Pengzhi ^a   Wang, Juan ^a   Xu, Ning ^a   Mi, Wenjuan ^a   Jiang, Xingwang ^a   Zhang, Changming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MESSENGER RNA; MICRORNA; MICRORNA 127; MICRORNA 137; MICRORNA 195; MICRORNA 22; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BCL2L2 PROTEIN, HUMAN; MIRN195 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BCL2L2 GENE; CANCER CELL; CANCER CELL LINE; CANCER RESISTANCE; CELL VIABILITY ASSAY; CHEMOSENSITIVITY; CHEMOSENSITIZATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG BINDING SITE; DRUG MECHANISM; DRUG SENSITIZATION; DRUG TARGETING; GENE; GENE EXPRESSION; GENE SILENCING; HT 29 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTERACTIONS WITH RNA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; BINDING SITE; BIOSYNTHESIS; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BINDING SITES; COLONIC NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; RNA, MESSENGER;

EID: 84920920979     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24366     Document Type: Article

References (49)

1. Abe R, Ueo H, Akiyoshi T. 1994. Evaluation of MTT assay in agarose for chemosensitivity testing of human cancers: Comparison with MTT assay. Oncology 51:416-425.
2. Bai H, Xu R, Cao Z, Wei D, Wang C. 2011. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett 585:402-408.
3. Bartel DP. 2009. MicroRNAs: Target recognition and regulatory functions. Cell 136:215-233.
4. Benchekroun MN, Sinha BK, Robert J. 1993. Doxorubicin-induced oxygen free radical formation in sensitive and doxorubicin-resistant variants of rat glioblastoma cell lines [corrected and republished erratum originally printed in FEBS Lett 1993 May 17;322(3):295-8]. FEBS Lett 326:302-305.
5. Binaschi M, Supino R, Gambetta RA, Giaccone G, Prosperi E, Capranico G, Cataldo I, Zunino F. 1995. MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: Alterations in cellular pharmacokinetics and in pattern of cross-resistance. Int J Cancer 62:84-89.
6. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM, Weinstein JN, Sadee W. 2008. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 7:1-9.
7. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT. 2008. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA 105:9053-9058.
8. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. 1986. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389.
9. Chen GQ, Zhao ZW, Zhou HY, Liu YJ, Yang HJ. 2010. Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med Oncol 27:406-415.
10. Climent J, Dimitrow P, Fridlyand J, Palacios J, Siebert R, Albertson DG, Gray JW, Pinkel D, Lluch A, Martinez-Climent JA. 2007. Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res 67:818-826.
11. Colombo V, Lupi M, Falcetta F, Forestieri D, D'Incalci M, Ubezio P. 2011. Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells. Cancer Chemother Pharmacol 67:369-379.
12. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, Deguchi T, Ito M. 2008. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 377:114-119.
13. Gottesman MM, Fojo T, Bates SE. 2002. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48-58.
14. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. 2006. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34:D140-D144.
15. Gross A, McDonnell JM, Korsmeyer SJ. 1999. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13:1899-1911.
16. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. 2010. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 15:673-682.
17. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Pure E, Agami R. 2008. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 10:202-210.
18. Kobayashi T, Lu J, Cobb BS, Rodda SJ, McMahon AP, Schipani E, Merkenschlager M, Kronenberg HM. 2008. Dicer-dependent pathways regulate chondrocyte proliferation and differentiation. Proc Natl Acad Sci USA 105:1949-1954.
19. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP. 2008. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7:2152-2159.
20. Lewis BP, Burge CB, Bartel DP. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15-20.
21. Li J, Zhang Y, Zhao J, Kong F, Chen Y. 2011. Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol Cell Biochem 357:31-38.
22. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, Ganesan S, Levine AJ, Rathmell WK, Bhanot GV. 2010. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol 4:51.
23. Liu T, Tang H, Lang Y, Liu M, Li X. 2009. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 273:233-242.
24. Lujambio A, Esteller M. 2007. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 6:1455-1459.
25. Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, Meyer HE, Reifenberger G. 2010. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 20:539-550.
26. Mei M, Ren Y, Zhou X, Yuan XB, Han L, Wang GX, Jia Z, Pu PY, Kang CS, Yao Z. 2010. Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat 9:77-86.
27. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. 2007. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:647-658.
28. Qi J, Yu JY, Shcherbata HR, Mathieu J, Wang AJ, Seal S, Zhou W, Stadler BM, Bourgin D, Wang L, Nelson A, Ware C, Raymond C, Lim LP, Magnus J, Ivanovska I, Diaz R, Ball A, Cleary MA, Ruohola-Baker H. 2009. microRNAs regulate human embryonic stem cell division. Cell Cycle 8:3729-3741.
29. Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, Bosia A. 2005. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 65:516-525.
30. Schramedei K, Morbt N, Pfeifer G, Lauter J, Rosolowski M, Tomm JM, von Bergen M, Horn F, Brocke-Heidrich K. 2011. MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Oncogene 30:2975-2985.
31. Sengupta S, Mantha AK, Mitra S, Bhakat KK. 2011. Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. Oncogene 30:482-493.
32. Simon SM, Schindler M. 1994. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 91:3497-3504.
33. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, Fodstad O, Ju J. 2009. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28:4065-4074.
34. Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson BG, Sidhu SB. 2009. miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res 15:7684-7692.
35. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. 2008. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 111:478-486.
36. Tao J, Lu Q, Wu D, Li P, Xu B, Qing W, Wang M, Zhang Z, Zhang W. 2011. microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep 25:1721-1729.
37. Tryndyak VP, Ross SA, Beland FA, Pogribny IP. 2009. Down-regulation of the microRNAs miR-34a, miR-127, and miR-200b in rat liver during hepatocarcinogenesis induced by a methyl-deficient diet. Mol Carcinog 48:479-487.
38. Tsuchiya N, Izumiya M, Ogata-Kawata H, Okamoto K, Fujiwara Y, Nakai M, Okabe A, Schetter AJ, Bowman ED, Midorikawa Y, Sugiyama Y, Aburatani H, Harris CC, Nakagama H. 2011. Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21. Cancer Res 71:4628-4639.
39. Ueda K, Cardarelli C, Gottesman MM, Pastan I. 1987. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84:3004-3008.
40. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN. 2006. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103:18255-18260.
41. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B. 2004. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem 279:25535-25543.
42. Weinlander G, Kornek G, Raderer M, Hejna M, Tetzner C, Scheithauer W. 1997. Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: High-dose oral tamoxifen and dexverapamil. J Cancer Res Clin Oncol 123:452-455.
43. Welch C, Chen Y, Stallings RL. 2007. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26:5017-5022.
44. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. 2009. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 50:113-121.
45. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A, Funato T, Yokomizo A, Naito S, Imoto I, Tsuruo T, Inazawa J. 2004. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 64:1403-1410.
46. Zenz T, Mohr J, Eldering E, Kater AP, Buhler A, Kienle D, Winkler D, Durig J, van Oers MH, Mertens D, Dohner H, Stilgenbauer S. 2009. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 113:3801-3808.
47. Zhang QQ, Xu H, Huang MB, Ma LM, Huang QJ, Yao Q, Zhou H, Qu LH. 2012. MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neuro Oncol 14:278-287.
48. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ. 2008. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283:31079-31086.
49. Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O, Tan M. 2009. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene 28:3689-3701.